Hepatitis C non-nucleoside (HCV-NN)
Biota has acquired considerable skills in identifying potential compounds that interfere with the replication of the hepatitis C virus. There are multiple targets available for potential drugs although almost all of these present considerable scientific challenge and there is significant intellectual property protection in the field.
Biota's solution
With HCV likely to evolve into a combination therapy market, much the same as HIV, novel compounds with alternate targets make considerable sense for Biota's early discovery approach.